Vargas HVM, Acosta AG

Idioma: Español
Referencias bibliográficas: 38
Paginas: 36-44
Archivo PDF: 76.31 Kb.

RESUMEN

El cáncer cervicouterino se desarrolla en mujeres infectadas por tipos específicos del virus del papiloma humano de alto riesgo u oncogénicos; el desarrollo de vacunas para la prevención de cáncer cervicouterino se está utilizando, particularmente en el adenocarcinoma cervical, el cual está incrementando su frecuencia y su detección se dificulta con los métodos de escrutinio vigentes. La citología cervicovaginal y colposcopia deben continuarse en mujeres inmunizadas con vacunas contra virus del papiloma humano y sus intervalos e indicaciones no se modifican de los programas de salud pública actuales. Las técnicas de biología molecular sensibles para identificar HPV de alto riesgo mejoran la capacidad de detección de lesiones escamosas intraepiteliales cervicales de alto grado, precursoras de cáncer cervicouterino representan un complemento a la citología. La aplicación de vacuna tetravalente para HPV (6, 11, 16 y 18) que causan infecciones por virus del papiloma humano, lesiones intraepiteliales escamosas de alto grado y cáncer cervicouterino, disminuye el riesgo cuando se aplica a mujeres núbiles durante la adolescencia, particularmente al inicio de la menarca, periodo de mayor riesgo oncológico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Salud Pública Mex 2007;vol.49(1):322-324 Tanaka-Kido Jorge(Glaxo Smith Klie S:A: de C:V:

2. Wright TC, Bosch FX, Franco EL et al. Chapter 30 HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006; 24 (Suppl 3): S251-261.

3. Vargas HVM. Virus del papiloma humano. Aspectos epidemiológicos, carcinogenéticos, diagnósticos y terapéuticos. Ginec Obstet Mex 1996; 64: 411.

4. Cervix cancer screening. Lyons: International Agency for Research on Cancer, 2005.

5. Lazcano PE. Salud Pública Mex 2007 vol 49(1):32-34

6. Zur Hausen H. Viruses in human cancers. Science 1991; 254: 1176-273.

7. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.

8. Cuzick J, Mayrand MH, Ronco G, Snijders PJ, Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006; 24 (Suppl 3): S90-7.

9. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157(3): 218-26.

10. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.

11. Muñoz N, Castellsague X, de Gonzalez AB, Gissman L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 (Suppl 3): S1-7.

12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.

13. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 779-80.

14. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88(1): 63-73.

15. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2003; 88(1): 63-73.

16. Clavel C, Cucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 2004; 90(9): 1803-8.

17. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191(5): 731-8.

18. Khan MJ, Castle PE, Lorìncz AT, Wacholder S, Sherman M, Scout DR et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(14): 1072-9.

19. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Charper 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (Suppl 3): S42-51.

20. Brown DR, Show ML, Qadadri B, Neptuno N. Vargas M, Tu W et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191(2): 182-92.

21. Parkin DM, Bray F. Charper 2: The Burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3): S11-25.

22. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109(3): 418-24.

23. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta- analysis. Br J Cancer 2003; 89(1): 101-5.

24. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Harbin M, Pendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367(9509): 489-98.

25. Lacey C, Lowndes CM, Shah KV. Charper 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006: 24 (Suppl 3): S35-41.

26. Villa LL, Aula KA, Giuliano AR, Costa RL, Petta CA, Andrade RP et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine 2006; 24 (27-28): 5571-83.

27. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367(9518): 1247-55.

28. Mao C, Koutsky LA, Aula KA, Wheeler CM, Brown DR, Wiley DJ et al. Efficacy of human papilloma-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107(1): 18-27.

29. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 young women: a randomized controlled trial. Lancet 2004; 364(9447): 1757-65.

30. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Charper 18 Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006; 24 (Suppl 3): S155-63.

31. Garnett GP, Kim JJ, French K, Goldie SJ. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 (Suppl 3): S155-63.

32. Goldie S, Kim J, Myers E. HPV vaccines, towards a new paradigm in cervical cancer prevention. Vaccine 2006; 24 (Suppl 3): S164-70.

33. Ho GY, Bierman R, Beardsley L, Chang CJ, Buró RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338(7): 423-8.

34. Wright TC, Van Damme P, Schmitt HJ, Meheus A. HPV vaccine introduction in industrialized countries. Vaccine 2006; 24 (Supple 3): S122-31.

35. Dillner J. The serological response to papillomavirus. Semin Cancer Biol 1999; 9(6): 423-30.

36. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004: 10(11): 1915-23.

37. Batson A, Meheus F, Brooks S. Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 2006; 24 (Suppl 3): S219-25.

38. Franco E, Cuzick J, Hildesheim A, de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24 (Suppl 3): S171-7.